<!DOCTYPE html>
<html lang='en'>
  <head>
    <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-PK63DK');</script>
    <meta content='text/html; charset=UTF-8' http-equiv='Content-Type'>
    <meta charset='utf-8'>
    <meta content='width=device-width, initial-scale=1, shrink-to-fit=no' name='viewport'>
    <link crossorigin='anonymous' href='https://stackpath.bootstrapcdn.com/bootstrap/4.1.1/css/bootstrap.min.css' integrity='sha384-WskhaSGFgHYWDcbwN70/dfYBj47jz9qbsMId/iRN3ewGhXQFZCSftd1LZCfmhktB' rel='stylesheet'>
    <link href='/styles.css' rel='stylesheet'>
    <title>Hetero Announces the Launch of Biosimilar Rituximab (MABALL(</title>
    <script async='async' src='https://www.googletagservices.com/tag/js/gpt.js'></script><script>var googletag=googletag ||{}; googletag.cmd=googletag.cmd || [];</script><script>googletag.cmd.push(function(){googletag.defineSlot('\/1010898\/sgforums_interstitial', [ 1.0 , 1.0], 'div-gpt-ad-1528181032761-0').setTargeting('forum', ['3513']).setTargeting('topic', ['489564']).addService(googletag.pubads()); googletag.defineSlot('\/1010898\/sgforums_leaderboard', [[ 728.0 , 90.0], [ 970.0 , 250.0]], 'div-gpt-ad-1528181032761-1').setTargeting('forum', ['3513']).setTargeting('topic', ['489564']).addService(googletag.pubads()); googletag.defineSlot('\/1010898\/sgforums_mpu', [ 300.0 , 250.0], 'div-gpt-ad-1528181032761-2').setTargeting('forum', ['3513']).setTargeting('topic', ['489564']).addService(googletag.pubads()); googletag.defineSlot('\/1010898\/sgforums_supersky', [ 160.0 , 600.0], 'div-gpt-ad-1528181032761-3').setTargeting('forum', ['3513']).setTargeting('topic', ['489564']).addService(googletag.pubads()); googletag.pubads().enableSingleRequest(); googletag.enableServices();});</script>
  </head>
  <body>
    <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-PK63DK"height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
    <div class='container'>
      <a href='/'>Home</a>
      >
      <a href='/forums/3513/'>PR Newswire Asia</a>
      <h1>Hetero Announces the Launch of Biosimilar Rituximab (MABALL(</h1>
      <nav class='pagination'>
      </nav>
      <ul class='list-group posts'>
        <li class='list-group-item post'>
          <div class='row'>
            <div class='col-md-2 meta'>
              <div class='author'>Helen.zhang</div>
              <time class='date' datetime='2015-08-07T15:19:58+00:00'>7 Aug 15, 15:19</time>
            </div>
            <div class='col-md body'>
              <div id="dvContent" style="font-size: 12px; line-height: 1.6em; color: #464646; word-wrap: break-word; font-family: Arial, Helvetica, sans-serif;">
              <p style="margin-top: 10px; margin-bottom: 10px; line-height: 1.6em;"><span class="xn-location" style="font-family: Arial, 'Times New Roman', Times, serif;">HYDERABAD, India</span> /PRNewswire/ --</p>
              <p style="margin-top: 10px; margin-bottom: 10px; line-height: 1.6em;">Hetero Group, one of <span class="xn-location" style="font-family: Arial, 'Times New Roman', Times, serif;">India's</span> leading generic pharmaceutical companies and one of the world's largest global producer of anti-retroviral drugs for HIV/AIDS treatment, today announces the successful launch of its biosimilar 'Rituximab' under the brand name <strong>MABALL</strong><strong><sup>[</sup></strong><sup>TM</sup><sup>]</sup> in <span class="xn-location" style="font-family: Arial, 'Times New Roman', Times, serif;">India</span>. It will be marketed and distributed by Hetero Healthcare Limited, a group company of Hetero.</p>
              <p style="margin-top: 10px; margin-bottom: 10px; line-height: 1.6em;">The launch of biosimilar Rituximab will provide a much needed access to patients in <span class="xn-location" style="font-family: Arial, 'Times New Roman', Times, serif;">India</span> suffering with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukaemia (CLL). Rituximab is recommended as the first-line treatment for NHL and is available in a single dose vial with two strengths - 100mg/10ml and 500mg/50ml.</p>
              <p style="margin-top: 10px; margin-bottom: 10px; line-height: 1.6em;">Commenting on the launch of the product, <strong>Dr B</strong><strong>andi</strong> <strong>P</strong><strong>arthasaradhi</strong><strong> Reddy, CMD, Hetero Group</strong> said: "The launch of MABALL strengthens Hetero's position in the biosimilar market, and has enabled the company to join select biotech companies with the capability to develop, manufacture and commercialize complex monoclonal antibodies (MAB's)."</p>
              <p style="margin-top: 10px; margin-bottom: 10px; line-height: 1.6em;">He further added, "Biosimilars is one of the key strategic business areas for Hetero. We have invested in biosimilars and will introduce more biosimilar MAB's in the future. We also have plans to introduce affordable biosimilar Rituximab into key markets outside <span class="xn-location" style="font-family: Arial, 'Times New Roman', Times, serif;">India</span> through our partners."</p>
              <p style="margin-top: 10px; margin-bottom: 10px; line-height: 1.6em;">Hetero's Rituximab is a biosimilar version of Roche's Rituximab. Rituximab is a monoclonal antibody used alone or with other drugs to treat Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukaemia and other indications such as Rheumatoid Arthritis.</p>
              <p style="margin-top: 10px; margin-bottom: 10px; line-height: 1.6em;"><span style="text-decoration: underline;"><strong>About Hetero</strong></span> </p>
              <p style="margin-top: 10px; margin-bottom: 10px; line-height: 1.6em;">Hetero is one of <span class="xn-location" style="font-family: Arial, 'Times New Roman', Times, serif;">India's</span> leading generic pharmaceutical companies and is one of the world's largest global producer of anti-retroviral drugs for the treatment of HIV/AIDS. Established by Dr. <span class="xn-person" style="font-family: Arial, 'Times New Roman', Times, serif;">B.P.S. Reddy</span> in 1993, Hetero is in the business of development, manufacturing and marketing of drug intermediates, active pharmaceutical ingredients (APIs), and finished dosages. Hetero is the largest privately-held pharmaceutical company and is one of the top 10 pharmaceutical companies in <span class="xn-location" style="font-family: Arial, 'Times New Roman', Times, serif;">India</span> with an annual turnover of US <span class="xn-money" style="font-family: Arial, 'Times New Roman', Times, serif;">$1.2 billion</span>. Hetero has over 25 state-of-the-art manufacturing facilities which has been approved by various regulatory authorities like US FDA, EU, WHO etc. With over 200 products in its portfolio across various therapeutic areas, Hetero has a strong global presence in over 120 countries and focuses on making affordable medicines accessible to patients worldwide. For more information, please visit <a style="margin: 0px; color: #6099e9; outline: none;" rel="nofollow" href="http://www.heteroworld.com/">http://www.heteroworld.com</a></p>
              <p style="margin-top: 10px; margin-bottom: 10px; line-height: 1.6em;"><span style="text-decoration: underline;"><strong>Media Contact: </strong></span><br><span class="xn-person" style="font-family: Arial, 'Times New Roman', Times, serif;">Jeyasingh Balakrishnan</span><br>Corporate Communications<br>Hetero Group<br>Contact: +91-9989626541/ <a style="margin: 0px; color: #6099e9; outline: none;" rel="nofollow" href="mailto:jeyasingh.b@heterodrugs.com">jeyasingh.b@heterodrugs.com</a></p>
              <p style="margin-top: 10px; margin-bottom: 10px; line-height: 1.6em;">Source: Hetero Group</p>
              </div>
              <div id="dvSource" style="font-size: 12px; margin-top: 25px; margin-bottom: 5px; color: #666666; font-family: Arial, Simsun, Helvetica, sans-serif; line-height: 12px;">Source: Hetero Group</div>
              <div class="dvWebsites" style="line-height: 1.5em; margin-top: 15px; color: #464646; font-family: Arial, Simsun, Helvetica, sans-serif; font-size: 12px;">Related Links:
              <ul style="margin: 0px; list-style: none;">
              <li><a style="margin: 0px; color: #6099e9; outline: none;" rel="nofollow" href="http://www.heteroworld.com/">http://www.heteroworld.com</a></li>
              </ul>
              </div>
            </div>
          </div>
        </li>
        <li class='list-group-item'>
          <div id='div-gpt-ad-1528181032761-2' style='height:250px; width:300px;'><script>googletag.cmd.push(function(){googletag.display('div-gpt-ad-1528181032761-2');});</script></div>
        </li>
      </ul>
      <nav class='pagination'>
      </nav>
      <footer>
        <nav class='nav'>
          <a class='nav-link' href='/'>Home</a>
          <a class='nav-link' href='/privacy/'>Privacy</a>
          <a class='nav-link' href='/terms/'>Terms</a>
        </nav>
      </footer>
    </div>
    <div id='div-gpt-ad-1528181032761-0' style='height:1px; width:1px;'><script>googletag.cmd.push(function(){googletag.display('div-gpt-ad-1528181032761-0');});</script></div>
  </body>
</html>
